CNP-201 in Subjects With Peanut Allergy
A Phase 1b/2a Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of CNP-201 in Subjects Ages 16-55 With Peanut Allergy
Sponsor: COUR Pharmaceutical Development Company, Inc.
Terminated
Lagging Enrollment and Administrative Reasons
Other terminated trials from COUR Pharmaceutical Development Company, Inc.
More terminations from COUR Pharmaceutical Development Company, Inc.
Other Peanut Allergy trials with similar outcome
A PHASE1 clinical study on Peanut Allergy, this trial is terminated or withdrawn. The trial is conducted by COUR Pharmaceutical Development Company, Inc. and has accumulated 13 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2024 — Jul 2024 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated · Phase: PHASE1_PHASE2 → PHASE1
-
Oct 2023 — Jan 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2023 — Oct 2023 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 8 earlier versions
-
Mar 2023 — Aug 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2023 — Mar 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2022 — Jan 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE1_PHASE2
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2022 — May 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- COUR Pharmaceutical Development Company, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .